39LOW

TRU

TRUSCREEN FPO NZX [TRU]
TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, and the Middle East/North Africa. It offers the TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to Truscreen Group Limited in August 2020. TruScreen Group Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.
Healthcare · ASX Small Cap
$0.0130 +8.3%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical51
Catalyst50
Sentiment50
Fundamental28
Momentum40
Risk Gate35
Get alerts when TRU's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track TRU — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic just turned bullish from a low level — early reversal sign
  • Volume surging at 2.3x normal while price falls — heavy selling pressure
  • Low cash runway (3 quarters) - dilution risk
  • Moderate P/S ratio (5.3x)
  • Revenue in sharp decline (-20%)
  • Near 52-week low (6% of range)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.75%/day)
  • Penny stock risk ($0.013)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-136%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 48% over the past year
  • Revenue declining at -20% — the top line is shrinking
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about TRU
"What's driving TRU's score?" "How does TRU compare to peers?" "Key risks for TRU?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Study Confirms Superiority of TRU and hr-HPV Co-testing
NONE Change of Director's Interest Notice
NONE Results Guidance FY2026

Recent ASX Announcements

2026-03-08 Study Confirms Superiority of TRU and hr-HPV Co-testing
2026-02-27 Change of Director's Interest Notice
2026-02-25 Results Guidance FY2026 PRICE SENSITIVE
2026-02-23 Management Update
2026-02-10 TruScreen Validated as Superior Primary Screening Tool PRICE SENSITIVE

Key Metrics

$9.7M
Market Cap
313K
Avg Volume
2.3x
Vol Ratio
$0.01 — $0.03
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-90.8%
ROE
-135.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 80%
LLeader vs LaggardlaggardRS: -3
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #91 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:TRU vs ATXTRU vs PNVTRU vs IMM
Scout Pro — Deeper Analysis for TRU
Try Pro free for 30 days
Share this analysis

Track TRU and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required